Elena Ambrogini Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

High Impact

Associate Professor

University of Arkansas for Medical Sciences

faculty

25 h-index 120 pubs 3,928 cited

Research Areas

Links

ORCID Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Elena Ambrogini's research group investigates mechanisms of bone loss and destruction, particularly in the context of aging and cancer metastasis. Her work has explored the role of senescent osteocytes in bone destruction associated with breast cancer metastasis, utilizing single-cell transcriptomic analysis. She has also studied the impact of Piezo1 on age-associated cortical bone loss and the potential contribution of osteocyte expression of osteoprotegerin to bone resorption following denosumab discontinuation. Her research extends to investigating signaling axes that regulate osteocyte function in multiple myeloma, including a novel CCL3-HMGB1 axis and a NOTCH3-CXCL12 axis that promotes chemoresistance.

Ambrogini's group has also examined the neutralization of oxidized phospholipids as a potential therapeutic strategy against age-associated bone loss in mice. In addition to her bone research, she has contributed to studies on the effect of androgen suppression on clinical outcomes in hospitalized men with COVID-19. With a h-index of 25 and over 3,900 citations across 120 publications, Ambrogini is recognized as a highly cited researcher. She collaborates extensively with colleagues at the University of Arkansas for Medical Sciences, including Charles A. O’Brien, Hayley M. Sabol, Japneet Kaur, and Aric Anloague.

Metrics

h-index: 25
Publications: 120
Citations: 3,928

Selected Publications

Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025) DOI
Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial (2025) DOI
Plasma levels of anti phosphocholine IgM antibodies are negatively correlated with bone mineral density in humans (2025) DOI
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024) DOI
Senolytics deplete senescent osteocytes and improve bone health in metastatic breast cancer (2024) DOI
Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis (2024) DOI
Editorial: Pathophysiology of bone and mineral metabolism (2024) DOI
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma (2024) DOI
OR27-02 The Bone Anabolic Effect Of An Antibody Blocking Oxidized Phospholipids Is Associated With An Increase In Wnt10b In Osteoblasts. (2023) DOI
THU664 Discontinuation Of Low-dose Levothyroxine Therapy For Patients With Subclinical Hypothyroidism Is Feasible: A Pilot, Randomized, Double-blind, Placebo-controlled Trial (2023) DOI
Retraction notice to “Deletion of the scavenger receptor Scarb1 in myeloid cells does not affect bone mass” [Bone 170(2023) 116702] (2023) DOI
Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation (2023) DOI
Piezo1 opposes age‐associated cortical bone loss (2023) DOI
RETRACTED: Deletion of the scavenger receptor Scarb1 in myeloid cells does not affect bone mass (2023) DOI
Deletion of the Scavenger Receptor Scarb1 in Myeloid Cells Does Not Affect Bone Mass (2022) DOI